Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

Amgen is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per ...

Sanofi SNY and partner Regeneron Pharmaceuticals, Inc. REGN announced a 60% cut in the U.S. list price of their PCSK9 inhibitor, Praluent, following a similar action last year by rival Amgen, Inc.

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Amgen announced the submission of an application to the Food and Drug Administration (FDA) seeking approval of a single-injection option for the monthly administration of the 420mg dose of Repatha ...

The FDA approved Amgen’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha’s approval comes a month ...

The Food and Drug Administration (FDA) has approved Repatha (evolocumab; Amgen) for the treatment of high cholesterol in certain adults. The Food and Drug Administration (FDA) has approved Repatha ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...

The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...